<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, there is no scientific evidence of the beneficial impact of IL-6 inhibitors in the modulation of the COVID-19 infection. Further understanding of the role of IL-6 reduction will be forthcoming as the pandemic progresses and further clinical data becomes available. 
 <italic>In vitro</italic> treatment with glycopyrronium, formoterol and budesonide exerted additive inhibitory effects on viral titers and cytokine production human nasal and tracheal epithelial cells.
</p>
